Brief: Fennec Pharmaceuticals Receives Positive CHMP Opinion For Pedmarqsi

Fennec Pharmaceuticals

31/03/2023 13:21

March 31 (Reuters) - Fennec Pharmaceuticals Inc
 FENC.O :
    * FENNEC PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION FOR
PEDMARQSI™ (SODIUM THIOSULFATE) TO REDUCE THE RISK OF HEARING
LOSS IN PEDIATRIC ONCOLOGY PATIENTS
    * FENNEC PHARMACEUTICALS INC - PEDMARQSI IS CURRENTLY
MARKETED AS
PEDMARK® IN U.S. FOLLOWING FDA-APPROVAL IN SEPTEMBER 2022
    * FENNEC PHARMACEUTICALS - CHMP'S RECOMMENDATION TO BE
REVIEWED BY
EUROPEAN COMMISSION, RATIFICATION OF CHMP RECOMMENDATION IS
EXPECTED BY EARLY JUNE

Source text for Eikon:  ID:nGNX2VbN41 
Further company coverage:  FENC.O 

 ((Reuters.Briefs@thomsonreuters.com;))